Ekso Bionics (NASDAQ:EKSO) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report report published on Wednesday morning. The brokerage issued a hold rating on the stock.

Separately, HC Wainwright upped their target price on shares of Ekso Bionics from $9.25 to $10.00 and gave the company a buy rating in a report on Tuesday, April 30th.

Ekso Bionics Stock Performance

NASDAQ:EKSO opened at $1.06 on Wednesday. The company has a fifty day simple moving average of $1.26 and a two-hundred day simple moving average of $1.63. The company has a market cap of $19.17 million, a price-to-earnings ratio of -1.09 and a beta of 1.49. The company has a quick ratio of 2.11, a current ratio of 2.81 and a debt-to-equity ratio of 0.33. Ekso Bionics has a 52 week low of $0.62 and a 52 week high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last issued its earnings results on Monday, April 29th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04). The firm had revenue of $3.76 million for the quarter, compared to analyst estimates of $4.99 million. Ekso Bionics had a negative return on equity of 95.36% and a negative net margin of 79.48%. During the same quarter in the previous year, the firm posted ($0.33) EPS. As a group, equities analysts anticipate that Ekso Bionics will post -0.43 earnings per share for the current fiscal year.

Institutional Trading of Ekso Bionics

A hedge fund recently raised its stake in Ekso Bionics stock. Kent Lake Capital LLC grew its holdings in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 596,050 shares of the company’s stock after acquiring an additional 454,892 shares during the period. Kent Lake Capital LLC owned about 3.28% of Ekso Bionics worth $811,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 6.42% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.